# Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients

> **NCT02532764** · PHASE1,PHASE2 · COMPLETED · sponsor: **ProQR Therapeutics** · enrollment: 70 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** QR-010
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02532764
- **Lead sponsor:** ProQR Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2017-09-14
- **Final completion:** 2017-09-14
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2019-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02532764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02532764, "Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02532764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*